CA3021231A1 - Pegylated bioactive peptides and uses thereof - Google Patents

Pegylated bioactive peptides and uses thereof Download PDF

Info

Publication number
CA3021231A1
CA3021231A1 CA3021231A CA3021231A CA3021231A1 CA 3021231 A1 CA3021231 A1 CA 3021231A1 CA 3021231 A CA3021231 A CA 3021231A CA 3021231 A CA3021231 A CA 3021231A CA 3021231 A1 CA3021231 A1 CA 3021231A1
Authority
CA
Canada
Prior art keywords
xaa
salt
peg
ala
ghrh analog
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3021231A
Other languages
English (en)
French (fr)
Inventor
Krishna G. Peri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Griffon Pharmaceuticals Inc
Original Assignee
Griffon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Griffon Pharmaceuticals Inc filed Critical Griffon Pharmaceuticals Inc
Publication of CA3021231A1 publication Critical patent/CA3021231A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA3021231A 2016-04-19 2017-04-18 Pegylated bioactive peptides and uses thereof Pending CA3021231A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662324600P 2016-04-19 2016-04-19
US62/324,600 2016-04-19
PCT/CA2017/050475 WO2017181277A1 (en) 2016-04-19 2017-04-18 Pegylated bioactive peptides and uses thereof

Publications (1)

Publication Number Publication Date
CA3021231A1 true CA3021231A1 (en) 2017-10-26

Family

ID=60039750

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3021231A Pending CA3021231A1 (en) 2016-04-19 2017-04-18 Pegylated bioactive peptides and uses thereof

Country Status (18)

Country Link
US (2) US10918730B2 (enExample)
EP (1) EP3445778B1 (enExample)
JP (1) JP7134093B2 (enExample)
KR (1) KR102520348B1 (enExample)
CN (1) CN109153712B (enExample)
AU (1) AU2017254754B2 (enExample)
BR (1) BR112018070929A2 (enExample)
CA (1) CA3021231A1 (enExample)
DK (1) DK3445778T3 (enExample)
ES (1) ES2824781T3 (enExample)
HU (1) HUE052802T2 (enExample)
IL (1) IL262356B2 (enExample)
MX (1) MX2018012716A (enExample)
PL (1) PL3445778T3 (enExample)
PT (1) PT3445778T (enExample)
RU (1) RU2748576C2 (enExample)
SG (1) SG11201808880PA (enExample)
WO (1) WO2017181277A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020205498A1 (en) 2019-03-29 2020-10-08 The General Hospital Corporation Ghrh or analogues thereof for use in treatment of hepatic disease
CN116194344B (zh) 2020-10-09 2026-06-30 奥托立夫开发公司 安全气囊装置
CN114195881B (zh) * 2021-12-16 2022-09-16 浙江湃肽生物股份有限公司 一种制备醋酸舍莫瑞林的方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4659693A (en) 1984-04-30 1987-04-21 Syntex (U.S.A.) Inc. N,N'-dialkyl substituted guanidino amino acyl residue substituted GRF-analog peptides
US4622312A (en) 1984-09-24 1986-11-11 Hoffmann-La Roche Inc. Growth hormone releasing factor analogs
US4689318A (en) 1985-08-29 1987-08-25 The Salk Institute For Biological Studies GRF analogs
US4914189A (en) 1987-02-05 1990-04-03 The Adminstrators Of The Tulane Educational Fund Synthetic GHRH analogs
DE3726324A1 (de) 1987-08-07 1989-02-16 Hoechst Ag Cyclopeptide als resorptionsfoerderer bei applikation auf die schleimhaeute
US5023322A (en) 1988-08-31 1991-06-11 Mta Kutatas-Es Szervezetelemzo Intezete Analogs of growth hormone releasing factor (GRF) and a method for the preparation thereof
US5084442A (en) 1988-09-06 1992-01-28 Hoffmann-La Roche Inc. Cyclic growth hormone releasing factor analogs and method for the manufacture thereof
US5137872A (en) 1989-09-18 1992-08-11 Pitman-Moore, Inc. Growth hormone-releasing factor analogs
NZ238748A (en) 1990-06-29 1993-09-27 Hoffmann La Roche Growth hormone releasing factor (grf) analogues
US5847006A (en) 1991-02-08 1998-12-08 Cambridge Neuroscience, Inc. Therapeutic guanidines
CA2084061A1 (en) 1991-04-09 1992-10-10 Arthur M. Felix Growth hormone releasing factor analogs
CA2158782C (en) 1994-09-23 2010-01-12 Pierrette Gaudreau Marker for growth hormone-releasing factor receptors
US5792747A (en) 1995-01-24 1998-08-11 The Administrators Of The Tulane Educational Fund Highly potent agonists of growth hormone releasing hormone
CA2218173A1 (en) 1995-04-14 1996-10-17 The Administrators Of The Tulane Educational Fund Analogs of growth hormone-releasing factor
DK0828758T3 (da) 1995-05-26 2002-01-07 Theratechnologies Inc Kimæriske fedtlegeme-pro-GRF-analoger med forøget biologisk potensering
EP0922446A1 (en) 1997-12-03 1999-06-16 Applied Research Systems Ars Holding N.V. Solution-phase site-specific preparation of GRF-PEG conjugates
US6696063B1 (en) 1998-12-30 2004-02-24 Applied Research Systems Ars Holding N.V. Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
KR20020047096A (ko) 1999-07-26 2002-06-21 크로커 사무엘 에스 초활성 돼지 성장 호르몬 분비 호르몬 유사체
US7256258B2 (en) 2000-10-05 2007-08-14 Ares Trading S.A. Regioselective liquid phase pegylation
EP1539959A2 (en) 2002-09-18 2005-06-15 Centre Hospitalier de l'Université de Montréal (CHUM) Ghrh analogues
WO2004067548A2 (en) 2003-01-31 2004-08-12 Theratechnologies Inc. Chemically modified metabolites of regulatory peptides and methods of producing and using same
AU2003229222B2 (en) 2003-05-29 2009-11-12 Theratechnologies Inc. GRF analog compositions and their use
US8293708B2 (en) * 2005-08-30 2012-10-23 Novo Nordisk Health Care A/G Liquid formulations N-terminal serine of pegylated growth hormone
EP1834962A1 (de) 2006-03-15 2007-09-19 Biotecon Therapeutics GmbH PEGyliertes mutiertes Clostridium botulinum Toxin
US20110021429A1 (en) 2007-10-01 2011-01-27 Pierrette Gaudreau Renoprotection by growth hormone-releasing hormone and agonists
US20110065633A1 (en) 2008-01-30 2011-03-17 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
US8796216B2 (en) 2008-06-12 2014-08-05 Syntaxin Limited Suppression of neuroendocrine diseases
BRPI0915142A8 (pt) 2008-06-12 2018-01-02 Syntaxin Ltd Polipeptídeos, ácido nucleico e usos dos mesmos
US20110288011A1 (en) 2008-12-05 2011-11-24 Jean-Paul Castaigne Peptide therapeutic conjugates and uses thereof
BR112013027150A2 (pt) * 2011-04-21 2017-06-06 Theratechnologies Inc thera
TW201806968A (zh) 2011-10-18 2018-03-01 艾利倫治療公司 擬肽巨環化合物
US9079974B2 (en) 2011-12-21 2015-07-14 The University Of Miami GH-RH analogs with potent agonistic effects
CN104946659A (zh) * 2015-03-27 2015-09-30 杭州北斗生物技术有限公司 重组人生长激素的制备方法及其peg化修饰物的制备方法
US20170037105A1 (en) * 2015-08-03 2017-02-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles

Also Published As

Publication number Publication date
EP3445778A4 (en) 2019-05-01
US20170296628A1 (en) 2017-10-19
PL3445778T3 (pl) 2021-02-22
RU2018140501A (ru) 2020-05-19
US10918730B2 (en) 2021-02-16
RU2748576C2 (ru) 2021-05-27
AU2017254754B2 (en) 2021-02-04
IL262356A (en) 2018-11-29
US20190209699A1 (en) 2019-07-11
KR102520348B1 (ko) 2023-04-10
US9988428B2 (en) 2018-06-05
EP3445778B1 (en) 2020-07-15
ES2824781T3 (es) 2021-05-13
PT3445778T (pt) 2020-10-15
DK3445778T3 (da) 2020-10-12
EP3445778A1 (en) 2019-02-27
BR112018070929A2 (pt) 2019-02-26
JP7134093B2 (ja) 2022-09-09
IL262356B2 (en) 2023-06-01
JP2019516675A (ja) 2019-06-20
RU2018140501A3 (enExample) 2020-09-08
CN109153712B (zh) 2022-09-16
SG11201808880PA (en) 2018-11-29
WO2017181277A1 (en) 2017-10-26
KR20180135016A (ko) 2018-12-19
HUE052802T2 (hu) 2021-05-28
CN109153712A (zh) 2019-01-04
AU2017254754A1 (en) 2018-11-01
MX2018012716A (es) 2019-02-11

Similar Documents

Publication Publication Date Title
RU2471867C2 (ru) Гиалуронидаза и способ ее применения
US9074014B2 (en) Analogues of glucose-dependent insulinotropic polypeptide
JP2015502336A5 (enExample)
ES2259834T3 (es) Peptidos que contienen lisina para el tratamiento de la enfermedad coronaria.
CA2489227A1 (en) Hla-a24-restricted cancer antigen peptides
KR20120093840A (ko) 옥시토신 수용체 작용제
RU2009119597A (ru) Новые белки н5, кодирующие их молекулы нуклеиновых кислот и векторы, и их применение в медицине
JP2022551153A (ja) 活性ポリペプチド化合物
CN101678084A (zh) 未酰基化的生长素释放肽作为治疗代谢紊乱中的治疗剂
BRPI0619399B1 (pt) Derivado de metastina ou um sal do mesmo, e, medicamento
JP2025163012A (ja) レトロインベルソペプチド
EP2766384B1 (en) Toll-like receptor 4 (tlr-4) agonist peptides for modulating tlr-4 mediated immune response
RU2018140501A (ru) Пэгилированные биологически активные пептиды и их применение
JP2019516675A5 (enExample)
WO2018031730A3 (en) Peptide inhibitors of phosphoglycerate mutase and methods of use
RU2015119472A (ru) Терапевтическое средство для бокового амиотрофического склероза
CN114364691B (zh) 作为纤维化基质积累的抑制剂的肽
WO2017149098A1 (en) Fusion respiratory syncytial virus inhibitors and use thereof
AU2020407264B2 (en) Macrocyclic peptides
CN112689513B (zh) 用于治疗格雷夫斯病的短环肽
US9850278B2 (en) Synthetic anti-inflammatory peptides and use thereof
AU671118B2 (en) Tachykinin antagonist tricyclic compounds, preparation of same and pharmaceutical compositions containing such compounds
CA2202496C (en) Neurotrophic peptides of activity dependent neurotrophic factor
WO2023061487A1 (zh) 一种抑制trpm8的多肽及其用途
CA3260499A1 (en) Peptide inhibitor and use thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220413

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241017

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241127

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241127

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NOTICE OF ALLOWANCE IS ISSUED

Effective date: 20250313

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250313

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250313

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B302 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - CONDITIONS FOR GRANT DETERMINED NOT COMPLIANT

Effective date: 20250714

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251002

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251209

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260601

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260703